ID   ABC3A_HUMAN             Reviewed;         199 AA.
AC   P31941; A0AVM1; Q12807; Q5JZ93; Q9UH18;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 3.
DT   22-JUL-2015, entry version 137.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3A;
DE            Short=A3A;
DE            EC=3.5.4.-;
DE   AltName: Full=Phorbolin-1;
GN   Name=APOBEC3A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 19-27; 31-35; 53-60;
RP   112-123; 129-137 AND 192-198, AND FUNCTION.
RC   TISSUE=Keratinocyte;
RX   PubMed=10469298; DOI=10.1046/j.1523-1747.1999.00682.x;
RA   Madsen P.P., Anant S., Rasmussen H.H., Gromov P., Vorum H.,
RA   Dumanski J.P., Tommerup N., Collins J.E., Wright C.L., Dunham I.,
RA   Macginnitie A.J., Davidson N.O., Celis J.E.;
RT   "Psoriasis upregulated phorbolin-1 shares structural but not
RT   functional similarity to the mRNA-editing protein apobec-1.";
RL   J. Invest. Dermatol. 113:162-169(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 53-60; 112-121 AND 129-137.
RC   TISSUE=Keratinocyte;
RX   PubMed=1286667; DOI=10.1002/elps.11501301199;
RA   Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E.,
RA   Vandekerckhove J.;
RT   "Microsequences of 145 proteins recorded in the two-dimensional gel
RT   protein database of normal human epidermal keratinocytes.";
RL   Electrophoresis 13:960-969(1992).
RN   [6]
RP   GENE FAMILY ORGANIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [7]
RP   REVIEW ON APOBEC FAMILIES.
RX   PubMed=12683974; DOI=10.1016/S0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family
RT   seeking roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [8]
RP   FUNCTION IN HOST DEFENSE.
RX   PubMed=12859895; DOI=10.1016/S0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R.,
RA   Bollman B., Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [9]
RP   FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION,
RP   MUTAGENESIS OF HIS-70; GLU-72 AND CYS-106, AND TISSUE SPECIFICITY.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I.,
RA   Landau N.R., Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [10]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [11]
RP   FUNCTION IN AAV INHIBITION, AND SUBCELLULAR LOCATION.
RX   PubMed=19461882; DOI=10.1371/journal.ppat.1000439;
RA   Narvaiza I., Linfesty D.C., Greener B.N., Hakata Y., Pintel D.J.,
RA   Logue E., Landau N.R., Weitzman M.D.;
RT   "Deaminase-independent inhibition of parvoviruses by the APOBEC3A
RT   cytidine deaminase.";
RL   PLoS Pathog. 5:E1000439-E1000439(2009).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, INDUCTION, AND ALTERNATIVE SPLICING
RP   (ISOFORMS 1 AND 2).
RX   PubMed=20615867; DOI=10.1074/jbc.M110.102822;
RA   Thielen B.K., McNevin J.P., McElrath M.J., Hunt B.V., Klein K.C.,
RA   Lingappa J.R.;
RT   "Innate immune signaling induces high levels of TC-specific deaminase
RT   activity in primary monocyte-derived cells through expression of
RT   APOBEC3A isoforms.";
RL   J. Biol. Chem. 285:27753-27766(2010).
RN   [13]
RP   FUNCTION IN FOREIGN DNA CLEARANCE, CATALYTIC ACTIVITY, TISSUE
RP   SPECIFICITY, AND INDUCTION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [15]
RP   FUNCTION IN DNA DEMETHYLATION.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [16]
RP   FUNCTION.
RX   PubMed=21460793; DOI=10.1038/embor.2011.46;
RA   Landry S., Narvaiza I., Linfesty D.C., Weitzman M.D.;
RT   "APOBEC3A can activate the DNA damage response and cause cell-cycle
RT   arrest.";
RL   EMBO Rep. 12:444-450(2011).
RN   [17]
RP   FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF ARG-28; HIS-29; LYS-30; ASN-57; LYS-60; ARG-69;
RP   GLU-72; TRP-98; ARG-128; TYR-130; ASP-131; ASP-133 AND TYR-136.
RX   PubMed=21123384; DOI=10.1128/JVI.01651-10;
RA   Bulliard Y., Narvaiza I., Bertero A., Peddi S., Roehrig U.F.,
RA   Ortiz M., Zoete V., Castro-Diaz N., Turelli P., Telenti A.,
RA   Michielin O., Weitzman M.D., Trono D.;
RT   "Structure-function analyses point to a polynucleotide-accommodating
RT   groove essential for APOBEC3A restriction activities.";
RL   J. Virol. 85:1765-1776(2011).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [19]
RP   FUNCTION.
RX   PubMed=21368204; DOI=10.1073/pnas.1009687108;
RA   Suspene R., Aynaud M.M., Guetard D., Henry M., Eckhoff G., Marchio A.,
RA   Pineau P., Dejean A., Vartanian J.P., Wain-Hobson S.;
RT   "Somatic hypermutation of human mitochondrial and nuclear DNA by
RT   APOBEC3 cytidine deaminases, a pathway for DNA catabolism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:4858-4863(2011).
RN   [20]
RP   REVIEW.
RA   Love R.;
RT   "Cytosine deaminases APOBEC3A, APOBEC3C, and APOBEC3H: Current
RT   understanding of their functional roles.";
RL   Student Perspec. Contemp. Virol. 0:0-0(2011).
RN   [21]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [22]
RP   FUNCTION.
RX   PubMed=22896697; DOI=10.1074/jbc.M112.385161;
RA   Carpenter M.A., Li M., Rathore A., Lackey L., Law E.K., Land A.M.,
RA   Leonard B., Shandilya S.M., Bohn M.F., Schiffer C.A., Brown W.L.,
RA   Harris R.S.;
RT   "Methylcytosine and normal cytosine deamination by the foreign DNA
RT   restriction enzyme APOBEC3A.";
RL   J. Biol. Chem. 287:34801-34808(2012).
RN   [23]
RP   INTERACTION WITH TRIB3, AND SUBCELLULAR LOCATION.
RX   PubMed=22977230; DOI=10.1074/jbc.M112.372722;
RA   Aynaud M.M., Suspene R., Vidalain P.O., Mussil B., Guetard D.,
RA   Tangy F., Wain-Hobson S., Vartanian J.P.;
RT   "Human Tribbles 3 protects nuclear DNA from cytidine deamination by
RT   APOBEC3A.";
RL   J. Biol. Chem. 287:39182-39192(2012).
RN   [24]
RP   FUNCTION IN HTLV-1 RESTRICTION.
RX   PubMed=22457529; DOI=10.1128/JVI.06570-11;
RA   Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.;
RT   "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-
RT   lymphotropic virus type 1.";
RL   J. Virol. 86:6097-6108(2012).
RN   [25]
RP   INTERACTION WITH AGO2.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [26]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) with restriction
CC       activity against viruses, foreign DNA and mobility of
CC       retrotransposons. Exhibits antiviral activity against adeno-
CC       associated virus (AAV) and human T-cell leukemia virus type 1
CC       (HTLV-1) and may inhibit the mobility of LTR and non-LTR
CC       retrotransposons. Selectively targets single-stranded DNA and can
CC       deaminate both methylcytosine and cytosine in foreign DNA. Can
CC       induce somatic hypermutation in the nuclear and mitochondrial DNA.
CC       May also play a role in the epigenetic regulation of gene
CC       expression through the process of active DNA demethylation.
CC       {ECO:0000269|PubMed:10469298, ECO:0000269|PubMed:12859895,
CC       ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:19461882,
CC       ECO:0000269|PubMed:20062055, ECO:0000269|PubMed:20615867,
CC       ECO:0000269|PubMed:21123384, ECO:0000269|PubMed:21368204,
CC       ECO:0000269|PubMed:21460793, ECO:0000269|PubMed:21496894,
CC       ECO:0000269|PubMed:22457529, ECO:0000269|PubMed:22896697}.
CC   -!- CATALYTIC ACTIVITY: Cytidine + H(2)O = uridine + NH(3).
CC       {ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055,
CC       ECO:0000269|PubMed:20615867, ECO:0000269|PubMed:21123384}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with AGO2. Interacts with TRIB3 (via N-
CC       terminus). {ECO:0000269|PubMed:22915799,
CC       ECO:0000269|PubMed:22977230}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1; Synonyms=Phorbolin-1;
CC         IsoId=P31941-1; Sequence=Displayed;
CC         Note=Enzymatically active.;
CC       Name=2;
CC         IsoId=P31941-2; Sequence=VSP_041723;
CC         Note=Enzymatically active.;
CC   -!- TISSUE SPECIFICITY: Expressed in peripheral leukocytes with higher
CC       expression in CD14-positive phagocytic cells. Highly expressed in
CC       keratinocytes and in periphery blood monocytes. Also detected in
CC       non-lymphoid tissues including lung and adipose tissues. Found at
CC       high levels in colorectal adenocarcinoma, Burkitt's lymphoma and
CC       chronic myelogenous leukemia. {ECO:0000269|PubMed:11863358,
CC       ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055,
CC       ECO:0000269|PubMed:20308164}.
CC   -!- INDUCTION: Up-regulated by interferon and CpG single-stranded DNA
CC       (at protein level). {ECO:0000269|PubMed:20062055,
CC       ECO:0000269|PubMed:20615867}.
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 CMP/dCMP-type deaminase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU01083}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U03891; AAA03706.2; -; mRNA.
DR   EMBL; CR456393; CAG30279.1; -; mRNA.
DR   EMBL; AL022318; CAI17897.1; -; Genomic_DNA.
DR   EMBL; BC126416; AAI26417.1; -; mRNA.
DR   CCDS; CCDS13981.1; -. [P31941-1]
DR   PIR; G01233; G01233.
DR   RefSeq; NP_001180218.1; NM_001193289.1. [P31941-1]
DR   RefSeq; NP_663745.1; NM_145699.3. [P31941-1]
DR   RefSeq; XP_011545347.1; XM_011547045.1. [P31941-1]
DR   UniGene; Hs.226307; -.
DR   PDB; 2M65; NMR; -; A=1-199.
DR   PDB; 4XXO; X-ray; 2.84 A; A/B=1-199.
DR   PDBsum; 2M65; -.
DR   PDBsum; 4XXO; -.
DR   ProteinModelPortal; P31941; -.
DR   SMR; P31941; 1-199.
DR   BioGrid; 128318; 2.
DR   DIP; DIP-61365N; -.
DR   STRING; 9606.ENSP00000249116; -.
DR   BindingDB; P31941; -.
DR   ChEMBL; CHEMBL1741179; -.
DR   PhosphoSite; P31941; -.
DR   BioMuta; APOBEC3A; -.
DR   DMDM; 12644206; -.
DR   PaxDb; P31941; -.
DR   PRIDE; P31941; -.
DR   DNASU; 200315; -.
DR   Ensembl; ENST00000249116; ENSP00000249116; ENSG00000128383.
DR   Ensembl; ENST00000402255; ENSP00000384359; ENSG00000128383.
DR   Ensembl; ENST00000570508; ENSP00000461288; ENSG00000262156.
DR   Ensembl; ENST00000618553; ENSP00000481904; ENSG00000128383.
DR   Ensembl; ENST00000623492; ENSP00000485234; ENSG00000262156.
DR   GeneID; 100913187; -.
DR   GeneID; 200315; -.
DR   KEGG; hsa:100913187; -.
DR   UCSC; uc003awn.2; human. [P31941-1]
DR   CTD; 100913187; -.
DR   CTD; 200315; -.
DR   GeneCards; GC22P039348; -.
DR   HGNC; HGNC:17343; APOBEC3A.
DR   HPA; HPA043237; -.
DR   MIM; 607109; gene.
DR   neXtProt; NX_P31941; -.
DR   PharmGKB; PA24891; -.
DR   eggNOG; NOG293254; -.
DR   GeneTree; ENSGT00530000062933; -.
DR   HOGENOM; HOG000033754; -.
DR   HOVERGEN; HBG050434; -.
DR   KO; K18750; -.
DR   OMA; LHNQAKN; -.
DR   OrthoDB; EOG71CFNW; -.
DR   PhylomeDB; P31941; -.
DR   TreeFam; TF331356; -.
DR   NextBio; 89887; -.
DR   PRO; PR:P31941; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; P31941; -.
DR   CleanEx; HS_APOBEC3A; -.
DR   Genevisible; P31941; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004126; F:cytidine deaminase activity; IDA:UniProtKB.
DR   GO; GO:0047844; F:deoxycytidine deaminase activity; IMP:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0044356; P:clearance of foreign intracellular DNA by conversion of DNA cytidine to uridine; IDA:UniProtKB.
DR   GO; GO:0009972; P:cytidine deamination; IDA:GOC.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0070383; P:DNA cytosine deamination; IDA:UniProtKB.
DR   GO; GO:0080111; P:DNA demethylation; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR007904; APOBEC_C.
DR   InterPro; IPR002125; CMP_dCMP_Zn-bd.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF05240; APOBEC_C; 1.
DR   SUPFAM; SSF53927; SSF53927; 1.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES_1; 1.
DR   PROSITE; PS51747; CYT_DCMP_DEAMINASES_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Antiviral defense;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Hydrolase;
KW   Immunity; Innate immunity; Metal-binding; Nucleus; Polymorphism;
KW   Reference proteome; Zinc.
FT   CHAIN         1    199       DNA dC->dU-editing enzyme APOBEC-3A.
FT                                /FTId=PRO_0000171752.
FT   DOMAIN       27    143       CMP/dCMP-type deaminase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01083}.
FT   ACT_SITE     72     72       Proton donor. {ECO:0000250}.
FT   METAL        70     70       Zinc; catalytic. {ECO:0000250}.
FT   METAL       101    101       Zinc; catalytic. {ECO:0000250}.
FT   METAL       106    106       Zinc; catalytic. {ECO:0000250}.
FT   VAR_SEQ       1     12       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_041723.
FT   VARIANT      19     19       T -> A (in dbSNP:rs17000556).
FT                                /FTId=VAR_048721.
FT   MUTAGEN      28     28       R->E: No effect on deaminase activity
FT                                despite an altered restriction activity
FT                                towards genetic invaders.
FT                                {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN      29     29       H->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN      30     30       K->F: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN      57     57       N->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN      60     60       K->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN      69     69       R->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN      70     70       H->R: Altered deaminase activity.
FT                                {ECO:0000269|PubMed:16527742}.
FT   MUTAGEN      72     72       E->Q: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:16527742,
FT                                ECO:0000269|PubMed:21123384}.
FT   MUTAGEN      98     98       W->L: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN     106    106       C->S: Altered deaminase activity.
FT                                {ECO:0000269|PubMed:16527742}.
FT   MUTAGEN     128    128       R->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN     130    130       Y->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN     131    131       D->N: No effect on deaminase activity
FT                                despite an altered restriction activity
FT                                towards genetic invaders.
FT                                {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN     133    133       D->N: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   MUTAGEN     136    136       Y->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders. {ECO:0000269|PubMed:21123384}.
FT   HELIX        15     21       {ECO:0000244|PDB:4XXO}.
FT   STRAND       24     26       {ECO:0000244|PDB:4XXO}.
FT   STRAND       27     29       {ECO:0000244|PDB:2M65}.
FT   STRAND       32     39       {ECO:0000244|PDB:4XXO}.
FT   STRAND       44     47       {ECO:0000244|PDB:2M65}.
FT   STRAND       53     56       {ECO:0000244|PDB:4XXO}.
FT   TURN         62     65       {ECO:0000244|PDB:4XXO}.
FT   HELIX        71     82       {ECO:0000244|PDB:4XXO}.
FT   STRAND       90     98       {ECO:0000244|PDB:4XXO}.
FT   TURN        103    105       {ECO:0000244|PDB:2M65}.
FT   HELIX       106    116       {ECO:0000244|PDB:4XXO}.
FT   STRAND      120    128       {ECO:0000244|PDB:4XXO}.
FT   HELIX       136    144       {ECO:0000244|PDB:4XXO}.
FT   TURN        145    147       {ECO:0000244|PDB:4XXO}.
FT   STRAND      148    152       {ECO:0000244|PDB:4XXO}.
FT   HELIX       155    164       {ECO:0000244|PDB:4XXO}.
FT   HELIX       179    195       {ECO:0000244|PDB:4XXO}.
SQ   SEQUENCE   199 AA;  23012 MW;  42E99E0D7DF7AA14 CRC64;
     MEASPASGPR HLMDPHIFTS NFNNGIGRHK TYLCYEVERL DNGTSVKMDQ HRGFLHNQAK
     NLLCGFYGRH AELRFLDLVP SLQLDPAQIY RVTWFISWSP CFSWGCAGEV RAFLQENTHV
     RLRIFAARIY DYDPLYKEAL QMLRDAGAQV SIMTYDEFKH CWDTFVDHQG CPFQPWDGLD
     EHSQALSGRL RAILQNQGN
//
